Skip to main content
SpringerLink
Log in

Letter to the Editor

Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia

  • Spotlight Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kurbegov D, Molldrem JJ . Immunity to chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 733–752.

    Article  Google Scholar 

  2. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657–662.

    Article  CAS  Google Scholar 

  3. Maziarz RT . Imatinib mesylate: a novel immune suppressive agent? Blood 2004; 104: 914–915.

    Article  CAS  Google Scholar 

  4. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.

    Article  CAS  Google Scholar 

  5. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.

    Article  CAS  Google Scholar 

  6. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S . Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.

    Article  CAS  Google Scholar 

  7. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538–544.

    Article  CAS  Google Scholar 

  8. Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105: 1135–1143.

    Article  CAS  Google Scholar 

  9. Steegmann JL, Moreno G, Alaez C, Osorio S, Granda A, de la Camara R et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 88: 762–768.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from PAR 2003, MIUR 2003, SIENAIL, Fondazione Monte dei Paschi, EHA clinical research grant 2004. The study was performed after approval by the local ethical committee and informed consent was obtained before patients were entered into the study.

Author information

Authors and Affiliations

  1. Department of Hematology, University of Siena, Siena, Italy

    M Bocchia, F Forconi, M Ippoliti, M T Pirrotta, D Raspadori, M Tozzi, A Gozzetti & F Lauria

  2. Department of Hematology, Roma ‘Tor Vergata’ University, Roma, Italy

    E Abruzzese & M M Trawinska

Authors
  1. M Bocchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Abruzzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Forconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Ippoliti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M M Trawinska
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M T Pirrotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Raspadori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Tozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Gozzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Lauria
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bocchia, M., Abruzzese, E., Forconi, F. et al. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 20, 142–143 (2006). https://doi.org/10.1038/sj.leu.2404029

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404029

  • Springer Nature Limited

This article is cited by

Search

Navigation